KR20160000318A - Cosmetic composition containing Fir tree oil - Google Patents
Cosmetic composition containing Fir tree oil Download PDFInfo
- Publication number
- KR20160000318A KR20160000318A KR1020140077545A KR20140077545A KR20160000318A KR 20160000318 A KR20160000318 A KR 20160000318A KR 1020140077545 A KR1020140077545 A KR 1020140077545A KR 20140077545 A KR20140077545 A KR 20140077545A KR 20160000318 A KR20160000318 A KR 20160000318A
- Authority
- KR
- South Korea
- Prior art keywords
- oil
- fir
- weight
- skin
- fermented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 239000002537 cosmetic Substances 0.000 title claims abstract description 23
- 239000010645 fir oil Substances 0.000 claims abstract description 73
- 230000037303 wrinkles Effects 0.000 claims abstract description 21
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 230000002087 whitening effect Effects 0.000 claims abstract description 11
- 239000003921 oil Substances 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 21
- 230000006872 improvement Effects 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 17
- -1 pack Substances 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 15
- 239000006210 lotion Substances 0.000 claims description 15
- 230000003020 moisturizing effect Effects 0.000 claims description 14
- 238000000855 fermentation Methods 0.000 claims description 13
- 230000004151 fermentation Effects 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 9
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 239000000686 essence Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 238000001256 steam distillation Methods 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 241000235649 Kluyveromyces Species 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 108010035532 Collagen Proteins 0.000 abstract description 11
- 102000008186 Collagen Human genes 0.000 abstract description 11
- 229920001436 collagen Polymers 0.000 abstract description 11
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 230000008099 melanin synthesis Effects 0.000 abstract description 8
- 230000007794 irritation Effects 0.000 abstract description 3
- 230000002500 effect on skin Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 53
- 235000019198 oils Nutrition 0.000 description 47
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000002304 perfume Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 5
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- GFVYDNHWTCHDSN-UHFFFAOYSA-N 14-methylpentadecyl octanoate Chemical compound CCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C GFVYDNHWTCHDSN-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 244000178606 Abies grandis Species 0.000 description 2
- 235000017894 Abies grandis Nutrition 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 231100000744 Human Cell Line Activation Test Toxicity 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000007218 ym medium Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- WCBPJVKVIMMEQC-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 WCBPJVKVIMMEQC-UHFFFAOYSA-N 0.000 description 1
- CRBBOOXGHMTWOC-NPDDRXJXSA-N 1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OCCO)[C@H]1OCCO CRBBOOXGHMTWOC-NPDDRXJXSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- YICVJSOYNBZJAK-UHFFFAOYSA-N 14-methylpentadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C YICVJSOYNBZJAK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000000405 Pinus densiflora Nutrition 0.000 description 1
- 240000008670 Pinus densiflora Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000003450 decanoic acid ester group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940078568 isocetyl myristate Drugs 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 전나무 오일을 포함하는 화장료 조성물 또는 피부 외용제에 관한 것이다. 본 발명의 전나무 오일 또는 발효된 전나무 오일은 항산화 효과, 탄력 개선 효과, 콜라겐 합성 효과가 우수하여 피부 주름 개선 효과가 뛰어나고, 멜라닌 합성 억제 효과가 우수하여 피부 미백 개선 효과가 뛰어나며, 피부에 알러지 반응이나 자극을 유발하지 않아서 사람의 피부에 안전하므로 화장료 및 피부 외용제로 사용 가능하다.The present invention relates to a cosmetic composition comprising fir oil or an external preparation for skin. The fir oil or fermented fir oil of the present invention is excellent in antioxidative effect, elasticity improving effect and collagen synthesis effect, so that it has excellent wrinkle improving effect on skin, excellent melanin synthesis inhibitory effect, excellent skin whitening effect, It is safe for human skin because it does not cause irritation, so it can be used as a cosmetic and skin external preparation.
Description
본 발명은 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 유효성분으로 포함하는 화장료 조성물 및/또는 피부 외용제에 관한 것이다.
The present invention relates to a cosmetic composition and / or an external preparation for skin comprising fir oil, fermented fir oil or a mixture thereof as an active ingredient.
피부는 외부 환경으로부터 인체를 보호하고, 내부의 수분 및 유용성분이 밖으로 유출되는 것을 막아주는 장벽기능, 체온조절 기능 및 배설 기능 등 다양한 생리적 기능을 담당하고 있는 중요한 기관이다. 그러나, 다음과 같은 이유 등에 의해 피부 세포의 활성이 저하되고 피부에 기미, 주근깨 및 검버섯 등의 변화가 생기며, 피부가 칙칙하고 거칠게 변하는 노화 현상이 일어나게 된다.The skin is an important body that is responsible for various physiological functions such as barrier function, body temperature control function and excretion function, which protects the human body from the external environment and prevents the internal moisture and oil components from leaking out. However, due to the following reasons, the activity of the skin cells is lowered, and the skin changes to spots, freckles and blotches, and the skin becomes dull and rough.
첫째, 피부의 진피층에 존재하는 콜라겐은 피부의 기계적 견고성, 결합 조직의 저항력, 조직의 결합력, 세포 접착의 지탱 등으로 피부의 구성성분에 중요한 기능을 한다. 이러한 콜라겐은 스트레스, 고령화 또는 자외선 조사에 의한 광노화에 의하여 감소되어, 피부 조직이 느슨해지며 탄력을 상실하게 된다.First, the collagen in the dermal layer of the skin plays an important role in the constituents of the skin due to the mechanical rigidity of the skin, the resistance of the connective tissue, the binding force of the tissue, and the support of the cell adhesion. Such collagen is reduced by photoaging due to stress, aging, or ultraviolet irradiation, and the skin tissue is loosened and the elasticity is lost.
둘째, 스트레스 또는 자외선 조사와 같은 외부요인에 의해 염증반응이 일어나거나 노화에 의해 면역세포들의 활성이 감소하여 피부의 면역기능 조절이 정상적이지 못하여 피부 노화가 촉진된다.Second, inflammation reaction occurs by external factors such as stress or ultraviolet ray irradiation, or activation of immune cells is reduced by aging, and skin aging is promoted because immune function regulation is not normal.
셋째, 표피의 세포기능이 저하되어 신진 대사 작용이 원활하지 못하여, 각질 탈락이 잘 일어나지 않아 각질이 과하게 축적된 상태에서 자외선을 받으면 탄력이 저하되어 주름의 발생을 초래하게 된다.Third, the cellular function of the epidermis is deteriorated, the metabolism is not smooth, and the exfoliation does not occur well, and when the ultraviolet light is received in the state where the keratin is overly accumulated, the elasticity is decreased and wrinkles are generated.
넷째, 표피에 피지막이 형성되지 않을 경우 수분과 피지 분비가 감소하고 피부가 건조해지면서 주름이 형성된다.Fourth, if no epidermis is formed on the epidermis, moisture and sebum secretion decrease, and the skin becomes dry and wrinkles are formed.
다섯째, 피하 지방에서 생성된 산소라디칼이 세포막과 세포핵을 파괴하여 혈액순환을 저하시킴으로써 피부의 영양과 수분이 부족하게되어 피부 노화가 촉진된다.Fifth, oxygen radicals generated from subcutaneous fat break down cell membranes and nuclei to lower blood circulation, and skin nutrition and moisture become insufficient and skin aging is promoted.
상기와 같은 피부 주름을 개선시키고 피부 노화를 지연시키기 위하여 다양한 연구가 진행되고 있으며, 고령화 사회로의 진입에 따라 젊고 탄력있는 피부를 갖고자 하는 소비자의 욕구가 증대되고, 2000년 7월 화장품법이 시행됨에 따라 피부 주름 개선 또는 피부 노화를 지연시키는 기능성 화장품에 대한 연구 및 개발이 더욱 활발해졌다. 이러한 기능성 화장품들은, 피부에 독성이나 자극을 주지 않기 위하여 한약재와 같은 천연물질을 사용하기도 한다. Various researches have been carried out to improve the wrinkles of the skin and to delay the aging of the skin. As the aging society enters, the consumer's desire to have young and resilient skin is increased, and the Cosmetic Act of July 2000 is implemented , Research and development of functional cosmetics that improve skin wrinkles or delay skin aging has become more active. These functional cosmetics may also use natural materials such as herbal medicines to avoid toxicity or irritation to the skin.
그 중 전나무(Abies grandis 또는 pinus grandis)는 소나무과에 속하는 상록침엽교목으로, 상기 전나무 잎을 채취하여 생으로는 위장병, 잇몸 병 등에 사용하고, 달인 물은 찜질하여 관절 치료용으로 사용되어 왔으나, 피부개선을 목적으로 사용한 전례는 없다.
Among them, fir (Abies grandis or pinus grandis) is an evergreen tree that belongs to Pinus densiflora. It is used for gastrointestinal diseases such as gastrointestinal diseases and gum disease, There is no precedent in the use of.
이에, 본 발명자들은 종래의 화장료 조성물에 비해 항산화 효과, 피부 보습 효과, 주름 개선 효과 및 미백 효과가 뛰어나며, 그 효과가 오래 지속되는 천연물질을 선별하던 중 전나무 오일을 피부에 도포할 경우 항산화 효과, 피부 보습 효과, 주름 개선 효과 및 피부 미백 효과가 개선됨을 확인함으로써 본 발명을 완성하게 되었다.Accordingly, the present inventors have found that when a natural substance having excellent antioxidative effect, skin moisturizing effect, wrinkle reducing effect and whitening effect is superior to a conventional cosmetic composition and long-lasting effect is applied, when fir oil is applied to skin, The skin moisturizing effect, the wrinkle improving effect and the skin whitening effect are improved, thereby completing the present invention.
따라서, 본 발명의 목적은 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 유효성분으로 포함하는 화장료 조성물을 제공하는데 있다.Accordingly, an object of the present invention is to provide a cosmetic composition comprising fir oil, fermented fir oil or a mixture thereof as an active ingredient.
또한, 본 발명의 다른 목적은 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 유효성분으로 포함하는 피부 외용제룰 제공하는데 있다.
Another object of the present invention is to provide an external preparation for skin comprising fir oil, fermented fir oil or a mixture thereof as an active ingredient.
상기 과제를 해결하기 위한 수단으로서, 본 발명은 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 유효성분으로 포함하는 화장료 조성물을 제공한다.
As means for solving the above problems, the present invention provides a cosmetic composition comprising fir oil, fermented fir oil or a mixture thereof as an active ingredient.
상기 과제를 해결하기 위한 다른 수단으로서, 본 발명은 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 유효성분으로 포함하는 피부 외용제를 제공한다.
As another means for solving the above problems, the present invention provides an external preparation for skin comprising fir oil, fermented fir oil or a mixture thereof as an active ingredient.
본 발명에 따른 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물은 항산화 효과, 탄력 개선 효과, 콜라겐 합성 효과 및/또는 멜라닌 합성 억제 효과가 우수하여 피부 주름 및 피부 미백을 상당히 개선시키면서도 피부에 알러지 반응이나 자극을 유발하지 않아서 사람의 피부에 안전하므로, 의약품 또는 화장료 등에 사용할 수 있다.
The fir oil, the fermented fir oil or the mixture thereof according to the present invention is excellent in antioxidative effect, elasticity improving effect, collagen synthesis effect and / or melanin synthesis inhibitory effect, and it is possible to improve skin wrinkles and skin whitening, And is safe for human skin, so that it can be used for medicines or cosmetics.
본 발명은 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 유효성분으로 포함하는 화장료 조성물 또는 피부 외용제에 관한 것이다.The present invention relates to a cosmetic composition or skin external preparation comprising fir oil, fermented fir oil or a mixture thereof as an active ingredient.
본 발명에서 전나무 오일은 전나무에서 추출한 것으로, 전나무의 잎, 뿌리, 줄기, 열매 또는 이의 혼합물에서 추출된 오일일 수 있으며, 구체적으로 전나무 잎에서 추출된 오일일 수 있다. In the present invention, fir oil is extracted from fir, and may be an oil extracted from foliage, roots, stem, fruit or a mixture thereof, and may be an oil extracted from fir leaf.
상기 전나무 오일은 전나무를 수증기 증류법(steam distillation)을 이용하여 추출하여 얻을 수 있는데, 상기 수증기 추출법은 수증기를 통해 증류하여 유용 성분을 수집하는 방법을 의미한다. The fir oil can be obtained by extracting fir by steam distillation. The steam extraction method refers to a method of collecting useful components by distillation through steam.
일 구체예에서, 수증기가 통과할 수 있도록 고안된 용기에 전나무를 넣고 수증기를 통과시키면, 전나무의 세포벽이 파괴되어 세포벽 사이의 에센스와 수증기가 모아지게 된다. 이들은 파이프를 통과하면서 냉각되어 증기는 증류액(수용액 성분)으로 에센스는 에센셜 오일(지용성 성분)으로 분리되는데, 상기 에센셜 오일은 가벼워 상층부에 존재하게 되므로, 상기 상부층을 분리함으로써, 에센셜 오일을 얻을 수 있다. In one embodiment, when fir is placed in a container designed to allow water vapor to pass through and water vapor is passed through it, the cell walls of the fir are destroyed and the essence and vapor between cell walls are gathered. They are cooled while passing through a pipe, and the steam is separated into a distillate (aqueous solution component) and an essence is separated into an essential oil (fat-soluble component). Since the essential oil is light and exists in the upper layer, have.
상기 수증기 추출법은 짧은 시간에 많은 양을 추출할 수 있다는 장점을 가진다. The steam extraction method has an advantage that a large amount can be extracted in a short time.
일 구체예에서, 전나무 오일은 전술한 수증기 추출법을 통해 추출된 에센셜 오일일 수 있다. In one embodiment, the fir oil may be an essential oil extracted via the above-described steam extraction method.
또한, 본 발명에서 발효된 전나무 오일은 전나무 오일의 발효물일 수 있다. In addition, the fir oil fermented in the present invention may be a fermentation product of fir oil.
상기 전나무 오일의 발효물은 전나무 오일을 클루이베로미세스 및 락토바실러스로 이루어진 군에서 선택된 종균으로 발효한 것일 수 있다. The fermented product of the fir oil may be one obtained by fermenting fir oil with seeds selected from the group consisting of Clostridium perfringens and Lactobacillus.
상기 발효는 10 내지 35℃ 에서 5일 내지 40 일 또는 5일 내지 30일 동안 이루어지는 것이 바람직하며, 상기 발효에 걸리는 시간은 발효 온도에 따라 달라질 수 있다. 또한, 본 발명에 사용되는 전나무의 상태에 따라 상기 발효 조건은 달라질 수 있으므로, 본 발명의 내용이 상기 예시된 발효 온도 및 발효 시간에 제한되는 것은 아니다.
Preferably, the fermentation is performed at 10 to 35 ° C for 5 to 40 days or 5 to 30 days, and the fermentation time may vary depending on the fermentation temperature. In addition, since the fermentation conditions may vary depending on the state of the fir used in the present invention, the content of the present invention is not limited to the fermentation temperature and fermentation time exemplified above.
본 발명은 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 유효성분으로 포함하는 항산화, 보습, 주름 개선, 탄력 개선 및 미백용 화장료 조성물을 제공할 수 있다.The present invention can provide a cosmetic composition for antioxidation, moisturizing, wrinkle improvement, elasticity improvement and whitening comprising fir oil, fermented fir oil or a mixture thereof as an active ingredient.
본 발명에 있어서, ‘항산화 효과’라 함은 세포내 대사 또는 자외선의 영향으로 인한 산화적 스트레스에 따라 반응성이 높은 자유 라디칼(free radical) 또는 활성산소종(reactive oxygen species;ROS)에 의한 세포의 산화를 억제하는 것을 말하며, 자유 라디칼 또는 활성산소종을 제거하여 이로 인한 세포의 손상이 감소되는 것을 포함한다.In the present invention, the term 'antioxidative effect' refers to the action of free radicals or reactive oxygen species (ROS), which are highly reactive according to oxidative stress caused by intracellular metabolism or ultraviolet rays, Refers to inhibition of oxidation, and includes removal of free radical or reactive oxygen species, thereby reducing damage to the cells.
본 발명에 있어서, ‘주름 개선 효과’라 함은 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다. In the present invention, the term " wrinkle-reducing effect " refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating already-generated wrinkles.
본 발명에 있어서, ‘미백 효과’라 함은 멜라닌 색소의 합성을 저해함으로써 피부 톤을 밝게 할 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착을 개선하는 것을 말한다.In the present invention, the 'whitening effect' refers to not only brightening the skin tone by inhibiting the synthesis of the melanin pigment but also improving skin hypercholesterolemia due to ultraviolet rays, hormones or heredity, such as spots or freckles.
본 발명의 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물의 유효성분은 화장료 조성물 총 중량 대비 0.0001 내지 30 중량% 로 포함되며, 화장료 조성물 총 중량 대비 0.005 내지 10 중량%로 포함되는 것이 보다 바람직하며, 0.01 내지 5 중량%로 포함되는 것이 더욱 바람직하다. 그 함량이 0.0001 중량% 미만일 경우에는 실질적인 피부 항산화 효과, 피부 보습 효과, 피부 주름 개선 효과 및 피부 미백 효과를 기대하기 어려우며, 30 중량%를 초과할 경우에는 화장학적 효과 대비 제조 비용이 너무 상승하는 문제점이 발생할 수 있다.The active ingredient of the fir oil, fermented fir oil or a mixture thereof of the present invention is contained in an amount of 0.0001 to 30% by weight based on the total weight of the cosmetic composition, more preferably 0.005 to 10% by weight based on the total weight of the cosmetic composition, By weight to 5% by weight. When the content is less than 0.0001% by weight, substantial skin antioxidative effect, skin moisturizing effect, skin wrinkle improving effect and skin whitening effect are hard to be expected. When the content is more than 30% by weight, Can occur.
전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 화장품으로 사용하는 경우, 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 유효성분으로 함유하여 제조되는 화장품은 일반적인 유화 제형 및 가용화 제형의 형태로 제조할 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등과 같은 화장수, 훼이셜 로션, 바디로션 등과 같은 유액, 영양 크림, 수분 크림, 아이 크림, 마사지 크림 등과 같은 크림, 에센스, 세럼, 화장연고, 스프레이, 오일젤, 젤, 팩, 선 스크린, 메이크업 베이스, 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션, 파우더, 클렌징 크림, 클렌징 로션, 클렌징 오일과 같은 메이크업 제거제, 클렌징 폼, 비누, 바디 워쉬 등과 같은 세정제 등의 제형을 가질 수 있다. When fir oil, fermented fir oil or a mixture thereof is used as a cosmetic product, the cosmetic product prepared by containing fir oil, fermented fir oil or a mixture thereof as an active ingredient can be produced in the form of a general emulsified formulation and a solubilized formulation . For example, creams, essences, serums, cosmetic creams, sprays, oil gels, gels, packs such as lotions such as lotion, facial lotion, body lotion and the like such as flexible lotion or nutrition lotion, nutrition cream, Such as powders, cleansing lotions, make-up removers such as cleansing oils, cleansing foams, soaps, bodywashes, and the like, such as sunscreen, makeup base, liquid type, solid type or spray type have.
상기 유연화장수는 본 발명의 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물 이외에 프로필렌글리콜, 글리세린 등의 다가 알코올 1 ~ 10 중량% 및 폴리에틸렌올레일에테르, 폴리옥시에틸렌 경화피마자유 등의 계면활성제 0.05 ~ 2 중량%를 함유하도록 제조할 수 있다.In addition to the fir oil, the fermented fir oil, or the mixture thereof, the softening agent may contain 1 to 10% by weight of a polyhydric alcohol such as propylene glycol or glycerin and 0.05 to 2% by weight of a surfactant such as polyethylene oleyl ether or polyoxyethylene hardened castor oil % ≪ / RTI > by weight.
상기 영양화장수 또는 영양크림은 본 발명의 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물 이외에 스쿠알란, 바셀린, 옥틸도데칸올 등의 오일 5 ~ 20 중량% 및 세탄올, 스테아릴알코올, 밀납 등의 왁스 3 ~ 15 중량%를 함유하도록 제조할 수 있다.The nutritional lotion or nutritional cream may contain 5 to 20% by weight of an oil such as squalane, petroleum jelly, octyldodecanol, etc., and wax 3 such as cetanol, stearyl alcohol, By weight to 15% by weight.
상기 마사지크림은 본 발명의 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물 이외에 유동파라핀, 바셀린, 이소노닐이소노나노에이트 등의 오일 30 ~ 70 중량%를 함유하도록 제조할 수 있다. The massage cream may be prepared so as to contain 30 to 70% by weight of an oil such as liquid paraffin, petrolatum, isononylisononanoate and the like in addition to fir oil, fermented fir oil or a mixture thereof of the present invention.
상기 에센스는 본 발명의 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물 이외에 프로필렌글리콜, 글리세린 등의 다가 알코올 5 ~ 30 중량%를 함유하도록 제조할 수 있다. The essence may be prepared so as to contain 5 to 30% by weight of a polyhydric alcohol such as propylene glycol or glycerin in addition to the fir oil, fermented fir oil or a mixture thereof of the present invention.
상기 팩은 본 발명의 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물 이외에 폴리비닐알코올 5 ~ 20 중량%를 함유하는 필 오프(peel off) 팩 또는 일반유화형 화장료에 카올린, 탈크, 산화아연, 이산화티탄 등의 안료가 5 ~ 30 중량% 함유된 워시 오프(wash off) 팩으로 제조할 수 있다. The pack may contain, in addition to fir oil, fermented fir oil or a mixture thereof, of the present invention a peel off pack containing 5 to 20% by weight of polyvinyl alcohol or a general emulsifying cosmetic containing kaolin, talc, zinc oxide, titanium dioxide And 5 to 30% by weight of a pigment such as a pigment or the like.
또한 본 발명의 화장료 조성물은 각각의 제형에 상기 기재한 성분들 이외에 일반적으로 화장료 조성물에 배합되는 유분, 물, 계면활성제, 보습제, 탄소수 1 내지 4의 저급 알코올, 증점제, 킬레이트제, 색소, 방부제 또는 향료 등을 필요에 따라 적절히 배합하여 사용할 수 있다.
In addition, the cosmetic composition of the present invention may further contain, in addition to the components described above, the components described above, such as oil, water, a surfactant, a moisturizer, a lower alcohol having 1 to 4 carbon atoms, a thickener, a chelating agent, Perfume and the like can be appropriately mixed and used as needed.
본 발명은 또한 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 유효성분으로 포함하는 항산화, 보습, 주름 개선, 탄력 개선 및 미백용 피부 외용제를 제공할 수 있다.The present invention can also provide antioxidative, moisturizing, wrinkle-improving, elasticity improving and whitening external preparations containing fir oil, fermented fir oil or a mixture thereof as an active ingredient.
전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 피부 외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다. When fir oil, fermented fir oil or a mixture thereof is used as an external preparation for skin, it may further contain a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, a softener, an antioxidant, a suspending agent, a stabilizer, , A perfume, a surfactant, water, an ionic or nonionic emulsifier, a filler, a sequestering and chelating agent, a preservative, a vitamin, a barrier, a wetting agent, a essential oil, a dye, a pigment, a hydrophilic or lipophilic active agent, Or any other ingredient conventionally used in external preparations for dermatological purposes. The components can also be introduced in amounts commonly used in the field of dermatology.
전나무 오일, 발효된 전나무 오일 또는 이의 혼합물이 피부 외용제 제형으로 제공될 경우, 이에 제한되는 것은 아니나, 연고, 패취제, 겔, 크림 또는 분무제와 같은 제형을 가질 수 있다.When fir oil, fermented fir oil or a mixture thereof is provided as a topical skin preparation, it may have a formulation such as, but not limited to, ointments, patches, gels, creams or sprays.
본 발명의 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물의 유효성분은 피부 외용제로 사용시 조성물 총 중량 대비 0.0001 내지 30 중량% 로 포함되며, 총 중량 대비 0.005 내지 10 중량%로 포함되는 것이 보다 바람직하며, 0.01 내지 5 중량%로 포함되는 것이 더욱 바람직하다. 그 함량이 0.0001 중량% 미만일 경우에는 실질적인 피부 항산화 효과, 피부 보습 효과, 피부 주름 개선 효과 및 피부 미백 효과를 기대하기 어려우며, 30 중량%를 초과할 경우에는 의약적 효과 대비 제조 비용이 너무 상승하는 문제점이 발생할 수 있다.The active ingredient of the fir oil, fermented fir oil or a mixture thereof of the present invention is used as an external preparation for skin when it is used in an amount of 0.0001 to 30% by weight based on the total weight of the composition, more preferably 0.005 to 10% by weight, More preferably 0.01 to 5% by weight. When the content is less than 0.0001% by weight, substantial skin antioxidative effect, skin moisturizing effect, skin wrinkle improving effect and skin whitening effect are hard to be expected. When the content is more than 30% by weight, Can occur.
본 발명의 피부 외용제는 유효량의 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 포함할 때 바람직한 주름 개선 효과, 항산화 효과, 보습 효과를 제공할 수 있다. 본 발명에 있어서, '유효량'이라 함은 주름을 개선하거나, 세포의 산화를 억제 또는 완화하거나, 보습 효과를 나타낼 수 있는 화합물의 양을 의미한다. 본 발명의 조성물에 포함되는 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물의 유효량은 조성물이 제품화되는 형태, 상기 화합물이 피부에 적용되는 방법 및 피부에 머무르는 시간 등에 따라 달라질 것이다. 예컨대, 상기 조성물이 의약품으로 제품화되는 경우에는 일상적으로 피부에 적용하게 되는 화장품으로 제품화되는 경우에 비해 높은 농도로 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물을 포함할 수 있을 것이다. 따라서, 일일 투여량은 전나무 오일, 발효된 전나무 오일 또는 이의 혼합물의 양을 기준으로 0.1 내지 100 ㎎/㎏이고, 바람직하게는 30 내지 80 ㎎/㎏이고, 더욱 바람직하게는 50 내지 60 mg/kg이며, 하루 1 ∼ 6 회 투여될 수 있다.
The external preparation for skin of the present invention can provide a desirable wrinkle-improving effect, antioxidative effect and moisturizing effect when an effective amount of fir oil, fermented fir oil or a mixture thereof is contained. In the present invention, the term "effective amount" means the amount of a compound capable of improving wrinkles, inhibiting or alleviating the oxidation of cells, or exhibiting a moisturizing effect. The effective amount of fir oil, fermented fir oil, or mixture thereof contained in the composition of the present invention will vary depending on the form in which the composition is commercialized, how the compound is applied to the skin, and the time on the skin. For example, when the composition is commercialized as a medicament, it may contain fir oil, fermented fir oil or a mixture thereof at a higher concentration than when it is commercialized as cosmetics that are routinely applied to the skin. Accordingly, the daily dosage is 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, based on the amount of fir oil, fermented fir oil or a mixture thereof And can be administered 1 to 6 times a day.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
실시예 Example
실시예Example 1. 전나무 잎 오일 1. Fir leaf oil
전나무 잎 오일로 AROMALAND INC(USA)사의 제품(파인 에센셜 오일 100%)을 사용하였다.
A product of AROMALAND INC (USA) (pine essential oil 100%) was used as fir leaf oil.
실시예Example 2. 발효 전나무 잎 오일 제조 2. Fermented fir leaf oil production
한국미생물보존센터에서 입수한 클루이베로미세스를 YM 배지에서 30℃의 온도 조건으로 배양하였다. 배양된 종균을 1 mL의 1회용 주사기로 실시예 1의 전나무 잎 오일에 10 ~ 1000 ㎕ 주사한 후 30℃, 85 ~ 90% 습도에서 일주일간 배양하였다. 발효가 충분히 이루어 지도록 10 ~ 35℃의 온도를 유지하면서 5 ~ 40 일 동안 발효를 진행하여 발효된 전나무 잎 오일 1 ~ 100 g을 수득하였다.
Cluye veromisses obtained from Korean Microorganism Conservation Center were cultured in YM medium at 30 ° C. The cultured seed bacterium was injected with 1 mL of disposable syringe to 10-1000 μl of the fir leaf oil of Example 1, followed by incubation at 30 ° C. and 85-90% humidity for one week. Fermentation was carried out for 5 to 40 days while keeping the temperature at 10 to 35 캜 so that sufficient fermentation was carried out to obtain 1 to 100 g of fermented fir leaf oil.
실시예Example 3. 발효 전나무 잎 오일 제조 3. Fermented fir leaf oil production
종균으로 클루이베로미세스 대신 한국미생물보존센터에서 입수한 락토바실러스를 사용하고, 배지로 MRS(deMan Rogosa Sharp)배지를 사용한 것을 제외하고는 실시예 2와 동일한 방법으로 발효 전나무 잎 오일 1 ~ 100 g을 수득하였다.
1 to 100 g of fermented fir tree leaf oil was prepared in the same manner as in Example 2, except that Lactobacillus obtained from the Korean Microorganism Conservation Center was used instead of Cluj Beromies as a seed and MRS (deMan Rogosa Sharp) medium was used as a medium. .
실시예Example 4. 발효 전나무 잎 오일 제조 4. Fermented fir leaf oil production
한국미생물보존센터에서 입수한 클루이베로미세스를 YM 배지에서 30℃의 온도 조건으로 배양했으며, 한국미생물보존센터에서 입수한 락토바실러스를 MRS(deMan Rogosa Sharp)배지에서 37℃의 온도 조건으로 배양하였다. 배양된 종균을 각각 1 mL의 1회용 주사기로 실시예 1의 전나무 잎 오일에 10 ~ 1000 ㎕에 주사한 후 30℃, 85 ~ 90% 습도에서 일주일간 배양하였다. 발효가 충분히 이루어 지도록 10 ~ 35℃의 온도를 유지하면서 5 ~ 40 일 동안 발효를 진행하여 발효 전나무 잎 오일 1 ~ 100 g을 수득하였다.
Clube Veromyces obtained from Korean Microorganism Conservation Center was cultured in YM medium at 30 ℃ and Lactobacillus obtained from Korean Microorganism Conservation Center was cultured at 37 ℃ in MRS (deMan Rogosa Sharp) medium. The cultured seeds were each injected into 1 to 1000 μl of the fir leaf oil of Example 1 with a 1-ml disposable syringe, followed by incubation at 30 ° C. and 85 to 90% humidity for one week. Fermentation was carried out for 5 to 40 days while keeping the temperature at 10 to 35 캜 so that sufficient fermentation was obtained to obtain 1 to 100 g of fermented fir tree leaf oil.
실험예Experimental Example 1. 세포독성시험 1. Cytotoxicity test
상기 실시예 1의 전나무 잎 오일, 실시예 2의 클루이베로미세스로 발효된 전나무 잎 오일, 실시예 3의 락토바실러스로 발효된 전나무 잎 오일 및 실시예 4의 클루이베로미세스 및 락토바실러스로 발효된 전나무 잎 오일의 안전성을 검증하기 위하여, 각각의 오일에 대하여 V79-4세포(차이니스햄스터, 폐조직 섬유아세포의 연속 세포주)를 배양하고 MTT 시험법을 수행하여 세포 독성을 조사하여, 그 결과를 하기 표 1에 나타냈다. 소디움라우릴설페이트(SLS)에 대해서도 같은 방법으로 세포 독성 시험을 실시하였다.
The fir leaf oil of Example 1, the fir leaf oil fermented by Cluerberomyces of Example 2, the fir leaf oil fermented by Lactobacillus of Example 3, and the fir leaf oil of Example 4, which were fermented with Cluerberomyces and Lactobacillus of Example 4 In order to verify the safety of the leaf oil, V79-4 cells (Chinese Hamster, continuous cell line of lung fibroblasts) were cultured for each oil, and MTT test was performed to examine cytotoxicity. Table 1 shows the results. Sodium lauryl sulfate (SLS) was also tested for cytotoxicity in the same manner.
* IC50(Inhibitory Concentration 50) - 50%의 세포를 사멸시키는 농도
* IC 50 (Inhibitory Concentration 50) - concentration to kill 50% of cells
상기 표 1로부터, 피부 외용제 또는 화장료 조성물에 사용되는 오일(실시예 1 내지 4)은 계면활성제인 소디움라우릴설페이트(SLS)에 비하여 낮은 세포 독성을 보여 안전성이 우수함을 확인할 수 있었다.
It can be seen from Table 1 that the oils used in the external preparation for skin or cosmetic composition (Examples 1 to 4) show lower cytotoxicity than sodium laurylsulfate (SLS), which is a surfactant, and thus are excellent in safety.
실험예Experimental Example 2. 2. 알러지allergy 평가(H- Evaluation (H- CLATCLAT ))
상기 실험예 1의 세포 독성 시험에서 안전한 것으로 확인된 본 발명의 오일(실시예 1 내지 4)의 알러지 유발 여부를 확인하기 위한 실험으로서, H-CLAT(Human Cell Line Activation Test) 실험을 실시하였다. The H-CLAT (Human Cell Line Activation Test) experiment was carried out as an experiment for confirming whether the oil of the present invention, which was confirmed to be safe in the cytotoxicity test of Experimental Example 1 (Examples 1 to 4), was allergic.
먼저 평가 대상 물질의 처리할 농도를 설정하기 위하여 사전 세포독성 실험을 실시하여 CV75(세포의 생존률이 75%인 농도)를 기준으로, CV75*1.2, CV75, CV75/1.23, CV75/1.25 및 수용성의 경우 10,000μg/ml, 비수용성의 경우 1,000μg/ml인 HTD(Highest technical dose)의 농도를 기준으로 위 농도까지 독성이 나타나지 않으면 이를 기준으로 처리농도를 설정하였다. 사전 세포독성 실험에서 설정된 처리농도로 THP-1(human monocytic cell line)에 물질을 접촉시키고 세포를 24시간 배양한 뒤 물질과 접촉한 THP-1 세포를 형광물질(FITC)이 표지된 항체로 염색하여, Isotype 대조군, CD54, CD86 검출을 Flow cytomertic 분석으로 확인하고 CD54, CD86의 검출량을 등급화하여 분류하였다. 이때, 알레르기 유발성 판정 기준에 따라 CD54 RFI(Relative fluorescence intensity) ≥ 200 및/또는 CD86 RFI(Relative fluorescence intensity) ≥ 150 이면 양성으로 판정하였다.
CV75 * 1.2, CV75, CV75 / 1.2 3 , CV75 / 1.2 5, and CV75 * 1.2 were selected based on the CV75 (the cell survival rate was 75% The treatment concentration was set based on the concentration of HTD (Highest technical dose), which is 10,000 μg / ml for water-soluble and 1,000 μg / ml for water-insoluble, The cells were contacted with THP-1 (human monocytic cell line) at a treatment concentration set in the pre-cytotoxicity experiment, and the cells were cultured for 24 hours. Then, the THP-1 cells in contact with the material were stained with a fluorescent antibody (FITC) Isotype control, CD54, and CD86 detection were confirmed by flow cytomatic analysis, and the detection quantities of CD54 and CD86 were classified and classified. At this time, the CD54 RFI (Relative fluorescence intensity) ≥ 200 and / or CD86 RFI (Relative fluorescence intensity) ≥ 150 were judged to be positive according to the criteria for allergy induction.
알러지 평과 결과 CD54 RFI ≤ 200, CD86 RFI ≤ 150 이므로 알러지 유발가능성이 없는 것으로 나타났다.
Allergic responses and results CD54 RFI ≤ 200, CD86 RFI ≤ 150, indicating no potential for allergy.
실험예Experimental Example 3. 3. 자유라디칼Free radical 소거능Scatters 확인 Confirm
상기 실시예 1 내지 4의 오일에 대한 자유라디칼 소거능을 1,1-디페닐-2-피크릴히드라질(DPPH) 방법으로 측정하였다(Blois, Nature 181, 1190, 1958). DPPH는 비교적 안정한 자유라디칼로서 라디칼 상태로 존재 시 517 ㎚에서 최대 흡광을 보이며, 라디칼이 소거되면 흡광성을 잃는다. DPPH는 시그마(Sigma)사의 것을 사용하였으며, 0.15 mM의 농도로 메틸알코올에 녹여 사용하였다. The free radical scavenging activity for the oils of Examples 1 to 4 was measured by the 1,1-diphenyl-2-picryl hydrazine (DPPH) method (Blois, Nature 181, 1190, 1958). DPPH is a relatively stable free radical, which shows maximum absorption at 517 ㎚ in the presence of radicals and loses its absorbance when the radicals are cleared. DPPH was purchased from Sigma, and dissolved in methyl alcohol at a concentration of 0.15 mM.
먼저, 상기 오일 및 비타민 C를 96-웰플레이트의 각각의 웰에 100 ㎕씩 넣었다. 여기에 DPPH 용액을 100 ㎕씩 첨가한 다음 상온에서 30 분간 방치한 후, Micro plate reader(BioTek EL-340)를 이용하여 517 ㎚에서의 흡광도를 측정하였다. 이때, 대조군으로는 메틸알코올을 사용하였다. First, 100 μl of the oil and vitamin C were added to each well of a 96-well plate. 100 μl of the DPPH solution was added thereto, and the mixture was allowed to stand at room temperature for 30 minutes. Then, the absorbance at 517 nm was measured using a microplate reader (BioTek EL-340). At this time, methyl alcohol was used as a control group.
시료를 처리한 것의 흡광도가 대조군의 흡광도의 절반이 될때의 오일의 농도를 IC50(Inhibitory Concentration 50)으로 표시하였으며, 그 결과를 하기 표 3에 나타냈다.
The IC 50 (Inhibitory Concentration 50) represents the concentration of the oil when the absorbance of the treated sample is half the absorbance of the control group. The results are shown in Table 3 below.
상기 표 3에 나타낸 바와 같이, 본 발명의 오일은, 자유라디칼 제거제로 알려진 비타민 C와 유사한 정도로 자유라디칼 소거능을 나타내어, 자유라디칼 소거능이 매우 강력하였음을 알 수 있었다.
As shown in Table 3, the oil of the present invention showed a free radical scavenging ability similar to that of vitamin C, which is known as a free radical scavenger, so that the free radical scavenging ability was very strong.
실험예Experimental Example 4. 콜라겐 합성 능력 평가 4. Evaluation of collagen synthesis ability
상기 실시예 1 내지 4의 오일에 대하여 콜라겐 합성 능력을 평가하였다. 생합성된 콜라겐 측정은 PICP EIA kit(Procollagen Type I C-Peptide Enzyme Immuno Assay KIT)를 이용하여 정량하였다.The collagen synthesis ability of the oils of Examples 1 to 4 was evaluated. The biocompatible collagen was quantitated using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immuno Assay Kit).
오일은 최종 농도가 10 ㎍/mL가 되도록 각각 인간유래 섬유아세포의 배양 배지에 첨가하고, 비타민 C는 최종농도가 52.8 ㎍/mL가 되도록 첨가하여, 각각 2 일 동안 배양하였다. 상기 배양된 배양액을 취하여 PICP EIA Kit를 사용하여 각 농도에서 콜라겐 생합성 정도를 분석하였다. 대조군으로서 무첨가 배양액을 사용하였다. 콜라겐 합성 능력은 무첨가 배양액에 대한 상대적인 콜라겐 합성률(%)로 계산하였으며, 그 결과를 하기 표 4에 나타냈다.
The oil was added to the culture medium of human-derived fibroblasts to a final concentration of 10 占 퐂 / mL, and vitamin C was added to a final concentration of 52.8 占 퐂 / mL and cultured for 2 days each. The cultured culture was taken and the degree of collagen biosynthesis at each concentration was analyzed using PICP EIA Kit. As a control group, a no-added culture medium was used. The collagen synthesis ability was calculated as the relative collagen synthesis ratio (%) relative to the culture without addition, and the results are shown in Table 4 below.
상기 표 4의 결과로부터, 배양된 인간유래 섬유아세포에 대하여 본 발명의 오일(실시예 1 내지 4)은 콜라겐 합성 능력이 우수함을 알 수 있으며, 그 중 혼합 균주로 발효한 실시예 4는 콜라겐 합성의 필수 영양소로 알려진 비타민 C와 유사한 수준의 콜라겐 합성 능력을 가지고 있음을 알 수 있었다.
From the results shown in Table 4, it can be seen that the oil of the present invention (Examples 1 to 4) has excellent collagen synthesis ability against cultured human-derived fibroblasts. Example 4, which is fermented as a mixed strain, Which is known as the essential nutrient of vitamin C.
실험예Experimental Example 5. 멜라닌 합성 5. melanin synthesis 억제능Inhibition 평가 evaluation
상기 실시예 1 내지 4의 오일에 대하여 멜라닌 합성 억제 능력을 평가하기 위하여 멜라닌 합성 세포인 멜라노사이트를 이용하여 다음과 같은 시험을 하였다. To evaluate the ability of the oils of Examples 1 to 4 to inhibit melanin synthesis, the following test was conducted using Melanocyte, a melanocyte synthesis cell.
오일은 최종농도가 10 ㎍/mL가 되도록 멜라노사이트 배양액에 첨가하고, 알부틴은 최종농도가 1mg/mL가 되도록 첨가한 후, 각각 1,500 rpm에서 5분 동안 원심분리하여 모으고, PBS 완충액으로 세척하였다. 그 후 추출 완충액(extraction buffer, 1% Nonidet P-40, 0.01% SDS, 0.1M Tris-HCl pH 7.2, protease inhibitor cocktail) 200 ㎕로 섭씨 4℃에서 1 시간 동안 추출하고 15,000 rpm에서 5분 동안 원심분리 하였다. 원심분리 결과 수득된 침전물을 1N NaOH로 처리하여 멜라닌을 녹이고 96-웰플레이트로 옮긴 후, ELISA reader(PowerWaveX340, Bio-tech Instruments, Inc.)를 이용하여 480 nm에서 흡광도를 측정하여 합성된 멜라닌의 양을 결정하였다. 그 후, 각 웰의 총 단백질의 양을 BCATM(Bicinchoninic acid) assay kit를 통해 정량하였고, 이 총 단백질의 양으로 합성된 멜라닌의 양을 보정하였다. 대조군으로서 무첨가 배양액을 사용하였다.The oil was added to the melanocyte culture to a final concentration of 10 / / mL, arbutin was added to a final concentration of 1 mg / mL, centrifuged at 1,500 rpm for 5 minutes each, collected and washed with PBS buffer. After that, extraction was carried out with 200 μl of extraction buffer (extraction buffer, 1% Nonidet P-40, 0.01% SDS, 0.1 M Tris-HCl pH 7.2, protease inhibitor cocktail) at 4 ° C for 1 hour and centrifuged at 15,000 rpm for 5 minutes Respectively. The resulting precipitate was treated with 1N NaOH to dissolve melanin and transferred to a 96-well plate. The absorbance was measured at 480 nm using an ELISA reader (PowerWaveX340, Bio-tech Instruments, Inc.) The amount was determined. Then, the amount of total protein in each well was quantified by BCA ™ (Bicinchoninic acid) assay kit, and the amount of synthesized melanin was corrected by the amount of total protein. As a control group, a no-added culture medium was used.
각 샘플 당 3회 반복 실험하였고, 멜라닌 합성 억제 능력은 대조군인 무첨가 배양액에 대한 상대적인 멜라닌 합성량을 합성 억제율(%)로 계산하여 그 결과를 하기 표 5에 나타냈다.
The experiment was repeated three times for each sample. The melanin synthesis inhibitory ability was calculated by the relative inhibition rate (%) of the melanin synthesis relative to the no-addition culture medium, which is the control group, and the results are shown in Table 5 below.
상기 표 5의 결과로부터, 배양된 쥐의 멜라노사이트에 대하여 본 발명의 오일(실시예 1 내지 4)은 멜라닌 합성을 효과적으로 억제하였다.
From the results shown in Table 5, the inventive oils (Examples 1 to 4) effectively inhibited melanin synthesis in the melanocytes of cultured rats.
비교예Comparative Example 1 및 1 and 실시예Example 5 내지 8. 수중유형 5 to 8. Underwater type 유화물Emulsion 제조 Produce
상기 실시예 1 내지 4 의 오일을 포함하는 수중유형 유화물(실시예 5 내지 8)을 제조하였다. 또한, 상기 오일을 포함하지 않는 수중유형 유화물을 비교예 1로서 제조하였다. 상세한 조성(중량%)은 하기 표 6에 나타냈다.
(Examples 5 to 8) containing the oil of Examples 1 to 4 were prepared. Further, an oil-in-water type emulsion was prepared as Comparative Example 1. The detailed composition (% by weight) is shown in Table 6 below.
(중량%)division
(weight%)
2. 모노스테아린산소르비탄 - 영국아이시아이(ICI)사이아라셀 60(Arlacel 60)
3. 이소세틸옥타노에이트 - 일본니혼고쿄알코올(Nihon KoKyu Alcohol)사의아이시이에이치 (ICEH)1. Carboxyvinyl polymer - a 1% by weight aqueous solution of Carbopol 941 from BF Goodrich, USA
2. Sorbitan monostearate - ICI Sialasel 60 (Arlacel 60)
3. Isocetyl octanoate - Ishihichi (ICEH) from Nihon KoKyu Alcohol Co.,
실험예Experimental Example 6. 피부 자극성 평가 6. Evaluation of skin irritation
상기 실시예 5 내지 9 및 비교예 1의 수중유형 유화물에 대하여 피부 자극성을 알아보기 위해 건강한 성인 남, 여 50명을 대상으로 등 부위에 각 시료의 일정량(0.2g)을 24시간 첩포한 후, 핀 챔버를 제거하고 4 시간 경과한 다음 육안으로 피부상태 변화를 판독하여, 그 결과를 표 7에 나타내었다.
To investigate the skin irritation of the underwater type emulsions of Examples 5 to 9 and Comparative Example 1, a predetermined amount (0.2 g) of each sample was applied to the back part of a healthy adult male and female for 24 hours, After the pin chamber was removed, the skin condition change was visually observed after 4 hours, and the results are shown in Table 7.
판정기준Criteria
-: 홍반이나 특이한 현상 없음.-: No erythema or unusual symptoms.
+-: 주위보다 약간 붉어짐+ -: slightly reddish from the surroundings
+: 주위보다 현저히 붉어짐+: Significantly reddened than surrounding
++: 주위보다 심하게 붉어지고 부풀어 오름.
++: More reddening and swelling than the surrounding area.
표 7에 나타낸 바와 같이, 실시예 5 내지 9의 수중유형 유화물이 음성 대조군인 증류수와 비슷한 정도의 낮은 피부 자극도를 나타낸 것으로 보아 피부에 안전하다는 것을 확인할 수 있었다.
As shown in Table 7, it was confirmed that the emulsions of the water type of Examples 5 to 9 showed low skin irritancy similar to that of distilled water, which is a negative control, and thus it is safe for skin.
실험예Experimental Example 7. 주름 개선 효과 7. Wrinkle improvement effect
상기 실시예 5 내지 9 및 비교예 1의 수중유형 유화물을 건강한 35 내지 50 세의 여성을 대상으로 하여 다음과 같은 방법으로 주름 개선 효과를 측정하였다.The wrinkle-reducing effect of the water-in-oil type emulsions of Examples 5 to 9 and Comparative Example 1 was measured in healthy 35- to 50-year-old women in the following manner.
35 내지 50 세의 여성 60 명을 10 명씩 6개의 군으로 나눈 후, 5 개의 군은 실시예 5, 내지 9의 수중유형 유화물을 안면부에 1 일 1 회씩 3 개월 간 도포하도록 하였고, 나머지 1 개의 군은 비교예 1의 수중유형 유화물을 안면부에 1 일 1 회씩 3 개월간 도포하도록 하였다.60 women aged 35 to 50 years were divided into 6 groups by 10 persons. Five groups were applied to the facial part of the water type emulsions of Examples 5 to 9 once a day for 3 months, and the remaining one group Was applied to the face of the underwater type emulsion of Comparative Example 1 once a day for 3 months.
3 개월 후 주름의 개선정도를 피시험자의 설문 및 주름의 영상 분석을 통해 평가하였다. 피시험자의 설문은 주름 개선 및 탄력 증진에 관하여 사용전과 비교하여 개선없음, 약간의 개선 및 상당한 개선의 3 단계로 판정하였으며, 그 결과를 하기 표 8에 나타내었다.
After 3 months, the improvement of wrinkles was evaluated by image analysis of questionnaires and wrinkles. The questionnaire of the subject was evaluated in three stages of improvement of wrinkles and improvement of elasticity, no improvement, slight improvement and significant improvement as compared with before use, and the results are shown in Table 8 below.
상기 표 8에 나타낸 바와 같이, 본 발명의 실시예 5 내지 9의 수중유형 유화물은 비교예 1의 수중유형 유화물에 비해 주름 개선 효과가 우수함을 확인할 수 있었다.
As shown in Table 8, it was confirmed that the underwater type emulsions of Examples 5 to 9 of the present invention had an excellent wrinkle reducing effect as compared with the underwater type emulsion of Comparative Example 1. [
실험예Experimental Example 8. 수분 8. Moisture 보유능Possession 평가 evaluation
상기 실시예 5 내지 9 및 비교예 1의 수중유형 유화물의 피부 보습력을 평가하기 위하여, 상기 수중유형 유화물을 각각 피부에 정량 도포한 후 각질층의 수분 보유량을 측정하고 이를 평가하는 방법을 사용하였다. 측정 기기로는 피부수분함량 측정기(스킨 설피스 하이그로미터, skin surface hygrometer, 모델명: SKICON-200, 일본 IBS사 제품)를 이용하였다. 구체적으로는, 25℃, 상대습도 45%의 항온 항습실에서 실시예 및 비교예의 수중유형 유화물를 각각 20명의 피시험자의 팔의 안쪽에 일정량(2 mg/㎠) 도포한 후 잘 문지르고, 평가 전의 수분 보유능을 기준으로 1 시간과 3 시간 후의 수분 증가율(%)을 측정하여 보습 효과를 평가하였다. 얻어진 결과를 하기 표 9에 나타내었다.
In order to evaluate the skin moisturizing ability of the underwater type emulsions of Examples 5 to 9 and Comparative Example 1, a method of measuring the water retention amount of the stratum corneum after the quantitative application of the above-mentioned water-in-water emulsions to the skin and evaluating them was used. As a measuring device, a skin moisture meter (skin surface hygrometer, model name: SKICON-200, manufactured by IBS Japan) was used. Specifically, in a constant temperature and humidity chamber at 25 ° C. and a relative humidity of 45%, a water-in-oil type emulsion of the Examples and Comparative Examples was applied to a predetermined amount (2 mg / cm 2) The moisture increase rate (%) after 1 hour and 3 hours was measured to evaluate the moisturizing effect. The obtained results are shown in Table 9 below.
상기 표 9에 나타낸 바와 같이, 본 발명의 실시예의 수중유형 유화물은 비교예의 수중유형 유화물에 비해 도포 1 시간 후 및 3 시간 후에 수분 보유 증가율이 훨씬 높아 보습 효과가 우수함을 알 수 있었다.As shown in Table 9, the water-in-oil emulsions of the examples of the present invention were much higher in moisturizing effect than the water-in-water emulsions of the comparative examples, after 1 hour and 3 hours after application.
실험예Experimental Example 9. 피부 탄력 효과 평가 9. Evaluation of skin elasticity effect
상기 실시예 5 내지 9 및 비교예 1의 수중유형 유화물의 피부 보습력을 평가하기 위하여 피부 탄력 개선 효과를 다음과 같이 평가하였다. In order to evaluate the skin moisturizing ability of the underwater type emulsions of Examples 5 to 9 and Comparative Example 1, the skin elasticity improving effect was evaluated as follows.
40 ~ 50대 여성에게 시험제품을 4주간 1일 2회 얼굴 전체에 사용하도록 하였다. 평가는 제품 사용 전 및 사용 4주 후 평가시점에서 Cutometer® MPA580을 이용하여 뺨 정면의 피부 탄력을 측정하여, 사용 전후의 탄력 개선율을 분석하였다. 분석결과를 하기 표 10에 나타내었다.
For women in their 40s and 50s, the test product was used twice a day for four weeks throughout the face. Before and after 4 weeks of use, skin elasticity of the cheek front was measured using Cutometer® MPA580, and the improvement rate of elasticity before and after use was analyzed. The results of the analysis are shown in Table 10 below.
(비교예1 대비)Elasticity improvement effect
(Compared to Comparative Example 1)
상기 표 10에 나타낸 바와 같이, 실시예의 수중유형 유화물은 사용 전과 비교하여 사용 4주 후 통계적으로 유의 차 있게 피부 탄력 개선 효과를 보이는 것을 알 수 있었다.
As shown in Table 10, it was found that the water-in-oil type emulsion of the Example exhibited statistically significant improvement in skin elasticity after 4 weeks of use as compared with before use.
제제예Formulation example 1. One. 화장료의Cosmetic 제조 Produce
1. 화장수 제조1. Lotion production
전나무 잎 오일, 발효된 전나무 잎 오일 또는 이의 혼합물 0.1 중량%, 글리세린 5.0 중량%, 디프로필렌글리콜 3.0 중량%, 히알루론산 0.5 중량%, 폴리옥시에틸렌 경화피마자유 0.1 중량%, 폴리에틸렌 올레일에테르 0.1 중량%, 에탄올 5.0 중량%, 방부제 0.15 중량%, 색소 0.05 중량％, 향료 0.05 중량％ 및 잔량의 정제수를 혼합(전체 조성 100 중량%)를 혼합하여 화장수를 제조하였다.
0.1% by weight of glycerin, 3.0% by weight of dipropylene glycol, 0.5% by weight of hyaluronic acid, 0.1% by weight of polyoxyethylene hardened castor oil, 0.1% by weight of polyethylene oleyl ether (Total composition: 100% by weight), 5.0% by weight of ethanol, 0.15% by weight of preservative, 0.05% by weight of pigment, 0.05% by weight of perfume and remaining balance were mixed to prepare a lotion.
2. 에센스 제조2. Essence manufacturing
전나무 잎 오일, 발효된 전나무 잎 오일 또는 이의 혼합물 0.1 중량%, 글리세린 5.0 중량%, 디프로필렌글리콜 3.0 중량%, 히알루론산 0.5 중량%, 폴리옥시에틸렌 경화피마자유 0.1 중량%, 폴리에틸렌 올레일에테르 0.1 중량%, 에탄올 5.0 중량%, 방부제 0.15 중량%, 색소 0.05 중량％, 향료 0.05 중량％ 및 잔량의 정제수를 혼합(전체 조성 100 중량%)를 혼합하여 화장수를 제조하였다.
0.1% by weight of glycerin, 3.0% by weight of dipropylene glycol, 0.5% by weight of hyaluronic acid, 0.1% by weight of polyoxyethylene hardened castor oil, 0.1% by weight of polyethylene oleyl ether (Total composition: 100% by weight), 5.0% by weight of ethanol, 0.15% by weight of preservative, 0.05% by weight of pigment, 0.05% by weight of perfume and remaining balance were mixed to prepare a lotion.
3. 로션 제조3. Lotion manufacturing
전나무 잎 오일, 발효된 전나무 잎 오일 또는 이의 혼합물 5.0 중량%, 세토스테아릴알코올 0.8 중량%, 자기 유화형 모노스테아린산 1.0 중량%, 밀납 0.5 중량%, 스테아린산 0.5 중량%, 유동파라핀 7.0 중량%, 스쿠알란 5.0 중량%, 마카데미아오일 3.0 중량%, 이소세틸옥타노에이트 2.0 중량%, 디메틸실록산 0.3 중량%, 모노스테아린산 소르비탄 0.5 중량%, 모노스테아린산 폴리에틸렌글리콜 1.2 중량%, 글리세린4.0 중량%, 프로필렌글리콜 4.0 중량%, 베타인 4.0 중량%, 카르복시폴리모 0.12 중량%, 트리에탄올아민 0.15 중량%, 방부제 0.25 중량%, 색소 0.05 중량％, 향료 0.05 중량％ 및 잔량의 정제수를 혼합(전체 조성 100 중량%)하여 로션을 제조하였다.
5.0 wt% of fir leaf oil, fermented fir leaf oil or a mixture thereof, 0.8 wt% of cetostearyl alcohol, 1.0 wt% of self emulsifying monostearate, 0.5 wt% of wax, 0.5 wt% of stearic acid, 7.0 wt% of liquid paraffin, 5.0% by weight, macadamia oil 3.0% by weight, isocetyl octanoate 2.0% by weight, dimethylsiloxane 0.3% by weight, monostearic acid sorbitan 0.5% by weight, monostearic acid polyethylene glycol 1.2% by weight, glycerin 4.0% by weight, propylene glycol (100% by weight of total composition) of 4.0% by weight, betaine 4.0% by weight, carboxypolymer 0.12% by weight, triethanolamine 0.15% by weight, preservative 0.25% by weight, coloring matter 0.05% by weight, To prepare a lotion.
4. 크림의 제조 4. Manufacture of cream
전나무 잎 오일, 발효된 전나무 잎 오일 또는 이의 혼합물 7.0 중량%, 세토스테아릴알코올 3.0 중량%, 자기유화형 모노스테아린산 0.5 중량%, 친유형 모노스테아린산 1.5 중량%, 밀납 0.5 중량%, 유동파라핀 8.0 중량%, 스쿠알란 7.0 중량%, 이소세틸옥타노에이트 4.0 중량%, 정제 호호바유 4.0 중량%, 디메틸실록산 0.3 중량%, 모노스테아린산소르비탄 1.0 중량%, 모노스테아린산폴리에틸렌글리콜 1.2 중량%, 글리세린 6.0 중량%, 프로필렌글리콜 4.0 중량%, 베타인 4.0 중량%, 잔탄검 0.06 중량%, 트리에탄올아민 0.10 중량%, 방부제 0.25 중량%, 향료0.05 중량％, 색소 0.05 중량％ 및 잔량의 정제수를 혼합(전체 조성 100 중량%)하여 크림을 제조하였다.
7.0 wt% of fir leaf oil, fermented fir leaf oil or a mixture thereof, 3.0 wt% of cetostearyl alcohol, 0.5 wt% of self emulsifying monostearic acid, 1.5 wt% of pro-type monostearic acid, 0.5 wt% of wax, 4.0% by weight of squalane, 4.0% by weight of isocetyl octanoate, 4.0% by weight of purified jojoba oil, 0.3% by weight of dimethylsiloxane, 1.0% by weight of monostearic acid sorbitan, 1.2% by weight of monostearic acid polyethylene glycol, (Whole composition: 100 wt%) was mixed with 4.0 wt% of propylene glycol, 4.0 wt% of betaine, 0.06 wt% of xanthan gum, 0.10 wt% of triethanolamine, 0.25 wt% of preservative, 0.05 wt% ) To prepare a cream.
제제예Formulation example 2: 피부 외용제의 제조 2: Preparation of external preparation for skin
1. 겔의 제조One. Preparation of gel
전나무 잎 오일, 발효된 전나무 잎 오일 또는 이의 혼합물 1.0 중량%, 글리세린 4.0 중량%, 프로필렌글리콜 4.0 중량%, 에탄올 10 중량%, 폴리옥시에틸렌 경화피마자유 0.1 중량%, 카르복시폴리머 0.30 중량%, 트리에탄올아민 0.30 중량%, 방부제 0.05 중량％, 색소 0.05 중량％, 향료 0.05 중량％, 잔량의 정제수를 혼합(전체 조성 100 중량%)하여 젤을 제조하였다.
1.0% by weight of glycerin, 4.0% by weight of propylene glycol, 10% by weight of ethanol, 0.1% by weight of polyoxyethylene hydrogenated castor oil, 0.30% by weight of carboxy polymer, 0.30% by weight of a preservative, 0.05% by weight of a preservative, 0.05% by weight of a coloring matter, 0.05% by weight of a perfume, and a remaining amount of purified water (100% by weight of total composition).
2. 연고의 제조2. Manufacture of ointment
전나무 잎 오일, 발효된 전나무 잎 오일 또는 이의 혼합물 0.5 중량％, 베타-1,3-글루칸 10.0 중량%, 밀납 10.0 중량%, 폴리솔베이트60 5.0 중량%, 피이지 60 경화피마자유 2.0 중량%, 솔비탄세스퀴올레이트 0.5 중량%, 바셀린 5.0 중량%, 유동파라핀 10.0 중량%, 스쿠알란 5.0 중량%, 쉐어버터 3.0 중량%, 카프릴릭/카프릭트리글리세라이드 5.0 중량%, 글리세린 10.0 중량%, 프로필렌글리콜 10.2 중량%, 트리에탄올아민 0.2 중량%, 방부제 0.05 중량％, 색소 0.05 중량％, 향료 0.05 중량％, 적량의 정제수를 혼합(전체 조성 100 중량%)하여 연고를 제조하였다.
0.5% by weight of fir leaf oil, fermented fir leaf oil or a mixture thereof, 10.0% by weight of beta-1,3-glucan, 10.0% by weight of wax, 5.0% by weight of Polysorbate 60, 2.0% A composition comprising 0.5% by weight of sorbitan sesquioleate, 5.0% by weight of vaseline, 10.0% by weight of liquid paraffin, 5.0% by weight squalane, 3.0% by weight of shea butter, 5.0% by weight of caprylic / capric triglyceride, 10.0% by weight of glycerin, Ointment was prepared by mixing 10.2% by weight of diethanolamine, 0.2% by weight of triethanolamine, 0.05% by weight of preservative, 0.05% by weight of pigment, 0.05% by weight of perfume and an appropriate amount of purified water.
3. 국소 투여용 약제(패취제)의 제조3. Preparation of topical medicines (patches)
전나무 잎 오일, 발효된 전나무 잎 오일 또는 이의 혼합물 0.5 중량%, 베타-1,3-글루칸 3.0 중량%, 헥실렌글리콜 20.0 중량%, 디에틸아민 0.7 중량%, 폴리아크릴산(Carbopol 934P) 1.0 중량%, 아황산나트륨 0.1 중량%, 폴리옥시에틸렌라우릴에테르(E.O=9) 1.0 중량%, 폴리히드록시에틸렌세틸스테아릴에테르(Cetomacrogol 1000) 1.0 중량%, 점성의 파라핀 오일 2.5 중량%, 카프릴산에스테르/카프르산에스테르(Cetiol LC) 2.5 중량%, 폴리에틸렌글리콜 400 3.0 중량%, 잔량의 탈이온수를 혼합(전체 조성 100 중량%)하여 패취제를 제조하였다.
0.5 wt% of beta-1, 3-glucan, 20.0 wt% of hexylene glycol, 0.7 wt% of diethylamine, 1.0 wt% of polyacrylic acid (Carbopol 934P) , 0.1% by weight of sodium sulfite, 1.0% by weight of polyoxyethylene lauryl ether (EO = 9), 1.0% by weight of polyhydroxyethylene cetyl stearyl ether (Cetomacrogol 1000), 2.5% by weight of viscous paraffin oil / Capric acid ester (Cetiol LC), 3.0% by weight of polyethylene glycol 400, and deionized water were mixed (100% by weight of the whole composition) to prepare a patch.
Claims (18)
Fir oil, fermented fir oil or a mixture thereof as an active ingredient.
전나무 오일은 전나무의 잎, 뿌리, 줄기, 열매 또는 이의 혼합물의 오일인 화장료 조성물.
The method according to claim 1,
Wherein the fir oil is an oil of leaves, roots, stem, fruit or a mixture thereof.
전나무 오일은 전나무를 수증기 증류법으로 추출하여 수득된 오일인 화장료 조성물.
The method according to claim 1,
Fir oil is an oil obtained by extracting fir by steam distillation method.
발효된 전나무 오일은 전나무 오일의 발효물인 화장료 조성물.
The method according to claim 1,
Wherein the fermented fir oil is a fermented product of fir oil.
전나무 오일의 발효물은 전나무 오일을 클루이베로미세스 및 락토바실러스로 이루어진 군에서 선택된 종균으로 발효한 발효물인 화장료 조성물.
5. The method of claim 4,
Wherein the fermented product of the fir oil is a fermented product obtained by fermenting the fir oil with the seed bacterium selected from the group consisting of Kluyveromyces and Lactobacillus.
발효는 10 내지 35 ℃에서 5 내지 40일 동안 수행하는 화장료 조성물.
6. The method of claim 5,
Wherein the fermentation is carried out at 10 to 35 DEG C for 5 to 40 days.
유효성분은 전체 조성물 총 중량 대비 0.0001 내지 30 중량%인 화장료 조성물.
The method according to claim 1,
Wherein the active ingredient is 0.0001 to 30% by weight based on the total weight of the total composition.
화장수, 로션, 크림, 에센스, 팩, 에멀젼, 오일젤, 세럼, 클렌징 폼, 메이크업 베이스, 파운데이션 또는 파우더로 이루어진 군으로부터 선택된 어느 하나의 제형인 화장료 조성물.
The method according to claim 1,
Wherein the cosmetic composition is any one selected from the group consisting of lotion, lotion, cream, essence, pack, emulsion, oil gel, serum, cleansing foam, makeup base, foundation or powder.
항산화, 보습, 주름 개선, 탄력 개선 또는 미백용인 화장료 조성물.
The method according to claim 1,
Antioxidant, moisturizing, wrinkle improvement, elasticity improvement or whitening.
Fir oil, fermented fir oil or a mixture thereof as an active ingredient.
전나무 오일은 전나무의 잎, 뿌리, 줄기, 열매 또는 이의 혼합물의 오일인 피부 외용제.
11. The method of claim 10,
Wherein the fir oil is an oil of leaves, roots, stem, fruit or mixture of fir.
전나무 오일은 전나무를 수증기 증류법으로 추출하여 수득된 오일인 피부 외용제.
11. The method of claim 10,
Fir oil is an oil obtained by extracting fir by steam distillation method.
발효된 전나무 오일은 전나무 오일의 발효물인 피부 외용제.
12. The method of claim 11,
Fermented fir oil is fermented product of fir oil.
전나무 오일의 발효물은 전나무 오일을 클루이베로미세스 및 락토바실러스로 이루어진 군에서 선택된 종균으로 발효한 발효물인 피부 외용제.
14. The method of claim 13,
Wherein the fermented product of the fir oil is a fermented product obtained by fermenting the fir oil with a seed bacterium selected from the group consisting of Cluj Beromiss and Lactobacillus.
발효는 10 내지 35 ℃에서 20일 내지 40일 동안 수행하는 피부 외용제.
15. The method of claim 14,
Wherein the fermentation is carried out at 10 to 35 DEG C for 20 to 40 days.
유효성분은 전체 조성물 총 중량 대비 0.0001 내지 30 중량%인 피부 외용제.
11. The method of claim 10,
Wherein the active ingredient is 0.0001 to 30% by weight based on the total weight of the total composition.
연고, 패취제, 겔, 크림 또는 분무제의 제형인 화장료 조성물.
11. The method of claim 10,
An ointment, a patch, a gel, a cream or a spray.
항산화, 보습, 주름 개선, 탄력 개선 또는 미백용인 피부 외용제.11. The method of claim 10,
Antioxidant, moisturizing, improving wrinkles, improving elasticity or whitening skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140077545A KR20160000318A (en) | 2014-06-24 | 2014-06-24 | Cosmetic composition containing Fir tree oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140077545A KR20160000318A (en) | 2014-06-24 | 2014-06-24 | Cosmetic composition containing Fir tree oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160000318A true KR20160000318A (en) | 2016-01-04 |
Family
ID=55164238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140077545A Withdrawn KR20160000318A (en) | 2014-06-24 | 2014-06-24 | Cosmetic composition containing Fir tree oil |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160000318A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200082397A (en) * | 2018-12-28 | 2020-07-08 | 주식회사 웰니스바이오 | Pharmaceutical composition for preventing or treating male sexual dysfunction |
| CN112912062A (en) * | 2018-10-16 | 2021-06-04 | 株式会社爱茉莉太平洋 | Skin barrier strengthening composition containing Abies sibirica oil |
-
2014
- 2014-06-24 KR KR1020140077545A patent/KR20160000318A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112912062A (en) * | 2018-10-16 | 2021-06-04 | 株式会社爱茉莉太平洋 | Skin barrier strengthening composition containing Abies sibirica oil |
| KR20200082397A (en) * | 2018-12-28 | 2020-07-08 | 주식회사 웰니스바이오 | Pharmaceutical composition for preventing or treating male sexual dysfunction |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8101214B2 (en) | Composition for skin external application containing complex of herbal extracts | |
| JP6968534B2 (en) | Topical composition containing Pichia anomala and chicory root extract | |
| EP3334501B1 (en) | Compositions including ampelopsis grossedentata and albizia julibrissin extracts and methods of use | |
| EP2174648B1 (en) | Skin-care compositions and uses thereof | |
| JP5948374B2 (en) | Method for producing cosmetic composition containing ginseng fruit agaric fermented liquid | |
| US11285093B2 (en) | Cosmetic uses of swertiamarin | |
| US8557795B2 (en) | Composition containing Chamaecyparis obtusa polysaccharides to be externally applied to the skin | |
| KR101663946B1 (en) | Cosmetic composition containing an ginsenoside Rg3 reinforced extract of fermentative Ginseng flower(Panax ginseng C. A. Meyer) by Aureobasidium pullulans | |
| KR101595530B1 (en) | Liposome composition having excellent effect of skin wrinkle improvement and skin whitening for accelerating percutaneous absorption | |
| KR20120003178A (en) | Skin whitening and moisturizing composition containing bee venom extract | |
| JP7033160B2 (en) | Vitamin D-like agent | |
| KR102142311B1 (en) | Skin external composition comprising tangeretin | |
| KR101860109B1 (en) | Skin external composition containing floral ginsenoside | |
| KR20160008942A (en) | A composition comprising fermented Myrothamnus flabellifolius extract and the use thereof | |
| KR20150137692A (en) | Cosmetic composition comtaining Lethariella cladonioides extracts | |
| KR102333132B1 (en) | Cosmetic Composition containing Frangipani Oil or Fermented Frangipani Oil | |
| KR20160000318A (en) | Cosmetic composition containing Fir tree oil | |
| KR20220082192A (en) | Cosmetic composition for anti-oxidation, skin whitening, and improving of skin wrinkle containing Sanguisorba officinalis extract | |
| KR101877803B1 (en) | Skin external composition containing floral ginsenoside | |
| KR100532633B1 (en) | Cosmetic composition having anti-inflammatory, skin-protecting, skin-elastic effects which comprise mixed plants extract | |
| KR20090075281A (en) | Cosmetic composition for improving atopic dermatitis | |
| KR20160081176A (en) | Skin external composition for moisturing skin or whitening skin comprising catechins and panaxydol | |
| KR101469810B1 (en) | Cosmetic composition containing Ginsenoside Rd and Ginsenoside F2 for improving skin wrinkle | |
| KR102419399B1 (en) | Cica-care cream composition and manufacturing method thereof | |
| KR20110126520A (en) | Cosmetic composition comprising extract of ginseng fermented with situation mushroom or ganoderma lucidum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20140624 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |